Slide 1: Investor Presentation with Q1 2026 Financial Highlights
INVESTOR PRESENTATION WITH Q1 2026 FINANCIAL HIGHLIGHTS
Slide 2: Forward Looking Statement Disclaimer
Forward Looking Statement Disclaimer CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This presentation includes information, statements, beliefs, and opinions which are forward-looking, and which reflect current estimates, expectations, and projections about future events, referred to herein
Slide 3: We're on a Mission to Improve Lives Through the Power of Cannabis
We’re on a Mission to Improve Lives Through the Power of Cannabis. 3
Slide 4: Our Growth Strategy
OUR GROWTH STRATEGY • Grow MariMed’s portfolio • Expand wholesale • Increase customer lifetime of leading cannabis brands penetration and asset-light value through retail Scale Distribution through innovation, market expansion through engagement, loyalty Expand the Brand Deepen Consumer category exp
Slide 5: MariMed by the Numbers
MARIMED BY THE NUMBERS $160M 900+ 9 13 2025 REVENUE EMPLOYEES STATES DISPENSARIES 7 52M+ 660+ 5 FACILITIES Cultivation and POPULATION WHOLESALE BRANDS Production ACCOUNTS #1 Edible & #5 Beverage ~526K+ sq ft (inc. PA facility under Mgmt.) ~$11b Across Core States TAM 5 Data as of March 2026
Slide 6: Why MariMed Wins
WHY MARIMED WINS Leading Cannabis CPG Platform Scalable Wholesale Engine Retail + Loyalty Ecosystem • #1 edible brand across core markets • 85% dispensary penetration • 398K loyalty members • Expanding beverage leadership • 660+ wholesale accounts • 80% of retail revenue tied to members • Portfolio
Slide 7: Footprint & Portfolio of Assets
FOOTPRINT & PORTFOLIO OF ASSETS 3 190 K 1 16K 2 5 2 107 K 33K 180K No. of dispensaries Cultivation & Processing (sq ft) (PA facility under management) 7
Slide 8: Wholesale: Driving Our Brand Momentum
WHOLESALE: DRIVING OUR BRAND MOMENTUM STRONG PERFORMANCE • Wholesale accounted for 44% of 1Q 2026 revenue BRAND PENETRATION • 84% penetration across core states for trailing 12 months thru 1Q 2026 STRATEGIC DISTRIBUTION • Product placements in >660 dispensaries across 6 states • Licensing third-part
Slide 9: A Portfolio of Top-Selling Brands
A PORTFOLIO OF TOP-SELLING BRANDS* • Betty’s Eddies - #1 edible in MA, MD & DE • Bubby’s Baked - #1 baked goods edible in MA, MD, DE & IL • Vibations Drink Mix – Top 10 beverage in MA, MD, DE & IL • InHouse – Top 10 gummy in MA, MD & DE *based on BDSA and Lit Alerts data for MA, MD, IL, and DE 9
Slide 10: Continuing to Expand Across Core Markets
CONTINUING TO EXPAND ACROSS CORE MARKETS Wholesale Revenue (in millions USD) Doors Coverage Ratio $69.6 $80.0 692 800 Growth Rate $70.0 $62.9 700 620 $60.0 $48.8 600 $50.0 500 410 $40.0 $32.9 400 $30.0 300 $20.0 200 $10.0 100 $0.0 26% 48% 29% 11% - 55% 83% 85% 2022 2023 2024 2025 2023 2024 2025 85%
Slide 11: Strong Retail Experience
STRONG RETAIL EXPERIENCE STRONG RETAIL BRAND & PRESENCE • 13 dispensaries across MA, IL, MD, DE, and OH • Strong presence under unified Thrive retail brand and website CONSUMER EXPERIENCE • Curated, wellness-focused retail environments with premium design • Deep community engagement with veterans, c
Slide 12: Strong Loyalty Member Growth
STRONG LOYALTY MEMBER GROWTH Members (Thousands) 450 Growth 398 Data-Driven Personalization Delivered: 400 364 342 350 316 • Membership +31% FY 25 vs FY 24 300 294 • Drove 80% of retail revenue in Q1 2026 250 200 • 2% higher avg basket vs non-members in Q1 2026 150 100 50 0 5% 7% 8% 7% 10% Q1 25 Q2
Slide 13: Management Team
MANAGEMENT TEAM Jon Levine Timothy Shaw Howard Schacter CEO & President Chief Operating Officer Chief Communications Officer Co-founder of MariMed with two Oversees all cultivation, production, and Veteran communications leader with decades in the cannabis industry. Led retail operations across 9 st
Slide 14: Our Results: Q1 2026 Financial Performance
OUR RESULTS: Q1 2026 FINANCIAL PERFORMANCE
Slide 15: Q1 2026 Financial Results
Q1 2026 FINANCIAL RESULTS • Revenue & Brand Momentum – Revenue increased 4% year over year despite ongoing Revenue $39.5 million industry pricing pressure across several core markets – Wholesale revenue grew 11% year over year, driven by continued expansion of MariMed’s leading edible and GAAP Gross
Slide 16: Balance Sheet - End of Q1 2026
BALANCE SHEET - END OF Q1 2026 • Enhanced Maturity Profile – Refinancing transaction extended weighted average debt maturity to approximately 4.6 years Cash and Cash Equivalents $7.9 million – Reduced near-term balance sheet overhang and improved capital structure stability – No material debt maturi
Slide 17: Q1 2026 Cash Flow
Q1 2026 CASH FLOW Cash Flow Category Q1 2026 Activity Positive cash flow Operating Activities $0.949 million from operations License renewals/purchases Investing Activities -$0.753 million and capital expenditures ~$1.1 million in scheduled debt Financing Activities -$1.143 million and financed leas
Slide 18: Year-end Non-GAAP Supplemental Information
Year-end Non-GAAP Supplemental information Income (loss) from Operations to Adjusted EBITDA Reconciliation (in ‘000s USD) 2020 2021 2022 2023 2024 2025 Income (loss) from operations 14,440 26,535 19,879 14,269 2,609 (2,820) Depreciation of property and equipment 1,792 2,098 3,432 5,549 7,910 8,109 A
Slide 19: Q1 2026 Non-GAAP Supplemental Information
Q1 2026 Non-GAAP Supplemental information (in ‘000s USD, except where noted) GAAP Income from operations 125 Depreciation of property and equipment 2,153 Stock-based compensation 325 Amortization of acquired intangible assets 810 Acquisition-related and other 169 Adjusted EBITDA 3,582 GAAP income fr
Slide 20: Q1 2026 Non-GAAP Supplemental Information
Q1 2026 Non-GAAP Supplemental information (in ‘000s USD, except where noted) GAAP Net loss (3,767) Stock-based compensation 325 GAAP Gross margin 38.7% Amortization of acquired intangible assets 810 Acquisition-related and other 169 Amortization of acquired 1.4% Gain on extinguishment of debt (699)
Slide 21: Thank You
THANK YOU For more information: Email: ir@marimedinc.com